Innovent Biologics, Inc. (IVBXF)
| Market Cap | 19.19B +2.2% |
| Revenue (ttm) | 2.31B +37.5% |
| Net Income | 181.43M +8.8% |
| EPS | 0.10 +3.1% |
| Shares Out | n/a |
| PE Ratio | 107.98 |
| Forward PE | 41.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 900 |
| Open | 11.00 |
| Previous Close | 11.10 |
| Day's Range | 11.00 - 11.06 |
| 52-Week Range | 9.10 - 15.01 |
| Beta | 0.36 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 25, 2026 |
About Innovent Biologics
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimum... [Read more]
News
Innovent's Sintbilo Cuts LDL Cholesterol Over 60% In Phase 3 Trial
(RTTNews) - Monday, November 9, 2026, Innovent Biologics, Inc. (IVBXF) announced its Phase 3 CREDIT-5 trial met its primary endpoint, with Sintbilo (tafolecimab) lowering LDL cholesterol by more than ...
Innovent Biologics announces Sintbilo achieved primary endpoint
Innovent Biologics (IVBXF) announced that its self-developed recombinant fully human anti-proprotein convertase subtilisin/kexin 9 monoclonal antibody, Sintbilo, has achieved its primary endpoint at w...
Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
PALO ALTO, Calif. and SUZHOU, China, Nov. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercia...
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential ...
Innovent Biologics presents Phase 2 data for IBI354 at ESMO Congress
Innovent Biologics (IVBXF) presented for the Phase 2 clinical data of its IBI354 as first-line treatment for breast cancer, BC, at the 2026 European Society for Medical Oncology, ESMO, Congress.
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and...
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and...
Innovent Reports Phase 3 Success For Arcotatug Tavatecan In Gastric Cancer
(RTTNews) - Innovent Biologics (1801.HK) announced positive results from its Phase 3 G-HOPE-001 study of arcotatug tavatecan (IBI343), an investigational CLDN18.2-targeted antibody-drug conjugate (ADC...
Innovent's Arcotatug Tavatecan Meets Phase 3 Endpoints In Gastric Cancer
(RTTNews) - Innovent Biologics (IVBXF) announced that its Phase 3 G-HOPE-001 study of arcotatug tavatecan met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in pre...
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED) SAN FRANCISC...
Innovent Biologics announces China NMPA approves Jaypirca for new indication
Innovent Biologics (IVBXF) announced that the China National Medical Products Administration has approved Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, as a monotherapy for the treatment ...
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial...
Innovent Biologics announces expansion of global Phase 3 MarsLight-11 trial
Innovent Biologics (IVBXF) announces expansion of the global Phase 3 MarsLight-11 trial, which is evaluating IBI363 in patients with squamous non-small cell lung cancer, NSCLC, whose disease has progr...
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali...
Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
Chinese biopharma stocks advanced Monday, with Innovent Biologics jumping 7% and Akeso up 8% after a report that the U.S. may allow most drug licensing deals with Chinese firms to continue. The propo...
Innovent Biologics Earnings release: H1 2026
Innovent Biologics released its H1 2026 earnings on August 25, 2026, summarizing the period's financial results.
Innovent Biologics Slides: H1 2026
Innovent Biologics has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 25, 2026.
Innovent Biologics Quarterly report: H1 2026
Innovent Biologics has published its H1 2026 quarterly earnings report on August 25, 2026.
Daiichi Sankyo, Innovent enter exclusive agreement for Vanflyta in China
Innovent Biologics (IVBXF) and Daiichi Sankyo (DSNKY) have entered into an exclusive agreement for the commercialization of Vanflyta in China. Under the terms of the agreement, Daiichi Sankyo will be…
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK...
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
Spero Therapeutics has licensed rights outside Greater China to develop and commercialize Innovent Biologics' experimental autoimmune disease treatment in a deal worth up to about $1.1 billion, the ...
Spero Therapeutics, Innovent Biologics enter license agreement for SP001
Spero Therapeutics (SPRO) and Innovent Biologics (IVBXF) announced an exclusive license agreement for SP001, a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to de...
Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement
Innovent Biologics (IVBXF) and Eli Lilly (LLY) jointly announced that they have entered into a distribution and promotion agreement regarding Lilly’s CDK4 & 6 inhibitor Verzenios in mainland China. In...
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tues...